Skip to main content
OpenTrials
Completed

NCT Number: NCT00900159

Effects of Daytime Eszopiclone Administration in Shift Workers

The purpose of this study is to test the effects of eszopiclone on daytime sleep and overnight wakefulness in shift workers.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Brigham & Women's Hospital

Boston, Massachusetts, 02115, United States

About this study

The current study seeks to extend the currently available treatments for SWSD by addressing the putative root cause of the problem-the inability of night-shift workers with or without SWSD- to obtain adequate daytime sleep in the face of the circadian drive for alertness that increases across the biological day. Even healthy, young subjects who are sleep-deprived overnight exhibit daytime sleep marked by frequent awakenings and low sleep efficiency, less slow-wave sleep, and altered sleep architecture, e.g. earlier predominance of REM sleep. Many night-workers routinely report 3-6 hours of habitual sleep duration for daytime sleep. Pharmacological interventions to decrease awakenings and improve total sleep time during daytime sleep could improve subsequent alertness during a night shift. Improving the wakefulness of night-shift workers over the nighttime could result in substantial benefits for the individual workers, improve workplace productivity and safety, and improve public health.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 20-50 (men or women)
  • Current shift worker (for at least 3 months, at least 5 overnights/month and 3 consecutive)
  • A willingness and ability to comply with study procedures
  • If of child-bearing potential, using a medically-accepted method of birth control, including abstinence, barrier method with spermicide, steroidal contraceptive (oral, transdermal, implanted, or injected) in conjunction with a barrier method, or intrauterine device [IUD]).

Exclusion criteria

  • Current diagnosis of DSM-IV Axis I disorder (other than insomnia)
  • Regular treatment (>1time/wk) with CNS-active medication within 1 month of first inpatient visit
  • Uncontrolled medical illness that would interfere with participation in the study
  • BMI>32 or < 19.8 kg/m2
  • Current symptoms or diagnosis of any moderate to severe sleep disorder other than SWSD
  • Periodic Leg Movement of Sleep Index (PLMSi)>20/hr of sleep or Respiratory Desaturation Index (RDI)>15 on polysomnography (PSG)
  • Current alcohol or drug dependence/abuse
  • Menopausal or peri-menopausal symptoms that disrupt sleep
  • Pregnant, lactating, or planning to become pregnant
  • Current smoking of more than 10 cigarettes per day
  • Current use of over the counter sleep aids such as Benadryl or melatonin

Treatment and study plan

Eszopiclone

Drug

3mg eszopiclone prior to daytime sleep for 3 days (at home) and 1 day (in lab)

Other names: Lunesta

Matching Placebo

Drug

matching placebo prior to daytime sleep for 3 days (at home) and 1 day (in lab)

Other names: placebo

Primary outcomes

  1. Nighttime Wakefulness Assessed by Mean Sleep Latency Across 4 Maintenance of Wakefulness Tests

    Time frame: On each treatment, after an 8.5 hour daytime sleep period following at least 3 consecutive night shifts

    Participants underwent four Maintenance of Wakefulness Tests (MWT) at 2-hour intervals during the simulated night shift starting 5 hours after wake time. MWT range from 0 to 40 minutes, where shorter times to fall asleep represent greater sleepiness (worse). MWT tests are averaged, for a mean in minutes.

Secondary outcomes

  1. EEG-recorded Sleep Efficiency

    Time frame: On each treatment, during an 8.5-hr daytime sleep episode following at least 3 consecutive night shifts

    Polysomnographic recordings of daytime sleep were made at sleep screen (8.5hr) and during daytime sleep episodes of 8.5 hours of duration during treatment visits. Sleep efficiency is calculated based on the time the participant spent in bed and the actual time the participant slept.

  2. Subjective Sleepiness and Performance

    Time frame: On each treatment, after an 8.5-hr daytime sleep episode following at least 3 consecutive night shifts

    The Karolinska Sleepiness Scale (KSS), a nine point Visual Analog Scale of alertness/sleepiness, was used to assess subjective sleepiness. The KSS is a scale from 1 to 9, from minimum to maximum sleepiness.

  3. Objective Vigilance Task Performance

    Time frame: On each treatment, after an 8.5 hour daytime sleep period following at least 3 consecutive night shifts

    A computer-based Flanker Task elicits responses to an incongruent pairing of stimuli measured as reaction time, in milliseconds. The Flanker task tests response inhibition, or the participants suppression of an unwanted response. A target stimulus (symbol) is "flanked" by non-target stimuli (symbols) that are the same as the target stimulus, opposite of the target stimulus, or neutral with respect to the target stimulus. The task is intended to assess the ability to maintain "selective attention" in the presence of distractors.

  4. Sleep-dependent Memory Consolidation

    Time frame: On each treatment, after an 8.5 hour daytime sleep period following at least 3 consecutive night shifts

    A computer-based Word-pair tasks is the number of words recalled after sleep from a list of words shown prior to going to sleep.

Sponsors and collaborators

Lead sponsor

Brigham and Women's Hospital

Other

Collaborators

  • Massachusetts General Hospital
  • Sumitomo Pharma America, Inc.

Registry information

Official study title

Effects of Daytime Eszopiclone Administration in Shift Workers on Overnight Wakefulness During a Subsequent Simulated Nightshift

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
May 12, 2009
Registry last updated
Aug 30, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.